NCT07230483RecruitingPhase 2
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.
Source: ClinicalTrials.gov · Last updated 17 Nov 2025
Brief summary (registry, in English)
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 246 (estimated)
- First submitted
- 13 Nov 2025
- Start date
- Dec 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- Keymed Biosciences Co.Ltd
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07230483
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 246
- From Dec 2025 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not enough washing-out period for previous therapy.
Other illness
- Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.
Who the study is looking for
- Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.